Doseology Sciences Settles Debt via Share Issuance

The settlement, intended to clear accrued compensation owed to a former consultant, aligns with Canadian Securities Exchange policies. The deemed price of $0.18 per share reflects the closing market value on the trading day prior to the announcement. These newly issued shares will remain subject to standard resale restrictions and hold periods mandated by Canadian securities laws.

Alongside the debt restructuring, the company confirmed a shift in its leadership team. Daniel Vice resigned from his position as a director effective September 17, 2026. Doseology continues to focus its operations on the growing market for functional, smokeless, and vapor-free oral pouches as a modern alternative to traditional tobacco delivery methods.